Cutibacterium Acnes Infection
Conditions
Brief summary
Infections on joint replacements remain one of the most serious complications of orthopaedic surgery. Despite improvements in skin preparation and antibiotic prophylaxis procedures, the risk of infection of joint prosthesis is still high, particularly for shoulder prostheses, especially in men. One of the bacteria most often involved in post-operative infections for shoulder prosthesis is Cutibacterium acnes (CA). This bacterium is one of the predominant bacteria in pilosebaceous units. Eradication of this micro-organism remains difficult despite the techniques used in the preoperative phase. The objective of this protocol is to evaluate the efficacy of applying a 5% benzoyl peroxide topical during the 5 days preceding the procedure in the surgical skin incision area, which is based on local acne treatment, on the reduction of the CA bacterial load in the dermis of the approach to shoulder arthroplasty in men.
Interventions
DRUG5% benzoyl peroxide
Application of 5% benzoyl peroxide during 5 days before the procedure
Sponsors
Nantes University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male patients, Adult patients, * Patient without a history of surgical intervention on the operated shoulder, * Patient managed for glenohumeral, partial (cup or anatomical hemi- arthroplasty) or total (anatomical or inverted) glenohumeral arthroplasty placement for primary osteoarthritis, or secondary to necrosis, massive rotator cuff tear or old fracture. * Patients affiliated to a social security system * Patients who have given their informed and written consent
Exclusion criteria
* Patient with arthroplasty for resumption of previous shoulder surgery or failure of arthroplasty * Patient with arthroplasty for acute trauma * Patient on immunosuppressantsimmunosuppressive drugs * Patient with inflammatory rheumatism * Patient with progressive cancer pathology * Allergies or intolerances concerning the modalities of selected skin preparations (Povidone Iodine, hypersensitivity to benzoyl peroxide) * Dermatological pathologies in the area to be treated * Acne treatment in the area to be treated within four weeks before inclusion * Patient without possible help from a third party for the application of Cutacnyl® 5% in the intervention group if necessary * Major under guardianship * Patient under the protection of justice * Patient not covered by social security
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients in each group with a positive Cutibacterium acnes sample at the dermis. | Day 0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Average number of positive Cutibacterium acnes skin samples before and after alcoholic surgical site antisepsis (5% alcoholic iodine povidone) in each of the two study groups | Day 0 | — |
| Incidence of Cutibacterium acnes shoulder prosthesis infections up to 2 years after shoulder prosthesis implantation in both study groups | 2 years | — |
| Phylotype | Day 0 | Determination of phylotype by molecular typing by Multi-Locus Sequence Typing and Single-Locus Sequence Typing techniques and comparison of Cutibacterium acnes strains by molecular biology and characterization of antibiotic resistance |
| Average number of positive intraoperative Cutibacterium acnes samples | Day 0 | samples taken at he cutaneous level before and after cutaneous antisepsis of the operating area before incision, fat and capsular. |
| Antibiotic resistance | Day 0 | — |
| Evaluation of the skin tolerance of the topical application from the skin tolerance scale (irritation, erythema and desquamation), at the time of inclusion and at D0 | Day 0 | skin tolerance scale evaluates local tolerance (absent: 0, light:1, moderate: 2 severe:3), erythema (absent:0, light:1, moderate:2, severe:3, very severe:4) and desquamation (absent: 0, light: 1, moderate: 2, severe: 3, very severe: 4) |
| Cutibacterium acnes strains | Day 0 | Comparison of Cutibacterium acnes strains by molecular biology |
Countries
France
Contacts
Primary ContactStéphane CORVEC
Outcome results
None listed